IMMUNOCLIN LIMITED

Company Registration Number:
03914021 (England and Wales)

Unaudited abridged accounts for the year ended 28 February 2023

Period of accounts

Start date: 01 March 2022

End date: 28 February 2023

IMMUNOCLIN LIMITED

Contents of the Financial Statements

for the Period Ended 28 February 2023

Company Information - 3
Balance sheet - 4
Additional notes - 6
Balance sheet notes - 9

IMMUNOCLIN LIMITED

Company Information

for the Period Ended 28 February 2023




Director: Dr Dorothy Bray
Mr Jonathan Bray
Secretary: Mr Jonathan Bray
Registered office: 2
Royal College Street
London
NW1 0NH
Company Registration Number: 03914021 (England and Wales)

IMMUNOCLIN LIMITED

Balance sheet

As at 28 February 2023


Notes

2023
£

2022
£
Fixed assets
Tangible assets: 4 5,545 7,383
Total fixed assets: 5,545 7,383
Current assets
Debtors: 41,235 43,537
Cash at bank and in hand: 5,113 23,133
Total current assets: 46,348 66,670
Creditors: amounts falling due within one year: ( 295,148 ) ( 305,113 )
Net current assets (liabilities): ( 248,800 ) ( 238,443 )
Total assets less current liabilities: ( 243,255 ) ( 231,060 )
Total net assets (liabilities): ( 243,255 ) ( 231,060 )

The notes form part of these financial statements

IMMUNOCLIN LIMITED

Balance sheet continued

As at 28 February 2023


Notes

2023
£

2022
£
Capital and reserves
Called up share capital: 10,000 10,000
Profit and loss account: ( 253,255 ) ( 241,060 )
Shareholders funds: ( 243,255 ) ( 231,060 )

For the year ending 28 February 2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 13 November 2023
And Signed On Behalf Of The Board By:

Name: Dr Dorothy Bray
Status: Director

Name: Mr Jonathan Bray
Status: Director

The notes form part of these financial statements

IMMUNOCLIN LIMITED

Notes to the Financial Statements

for the Period Ended 28 February 2023

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

IMMUNOCLIN LIMITED

Notes to the Financial Statements

for the Period Ended 28 February 2023

  • 2. Employees


    2023

    2022
    Average number of employees during the period 0 0

IMMUNOCLIN LIMITED

Notes to the Financial Statements

for the Period Ended 28 February 2023

  • 3. Off balance sheet disclosure

    No

IMMUNOCLIN LIMITED

Notes to the Financial Statements

for the Period Ended 28 February 2023

4. Tangible Assets

Total
Cost £
At 01 March 2022 325,270
Additions -
Disposals -
Revaluations -
Transfers -
At 28 February 2023 325,270
Depreciation
At 01 March 2022 317,887
Charge for year 1,838
On disposals -
Other adjustments -
At 28 February 2023 319,725
Net book value
At 28 February 2023 5,545
At 28 February 2022 7,383

IMMUNOCLIN LIMITED

Notes to the Financial Statements

for the Period Ended 28 February 2023

5. Revaluation reserve


2023
£
Balance at 28 February 2023 0